Blog

Landmark data from the phase 3 SOLO-1 (NCT01844986) and SOLO-2 (NCT01874353) trials collectively established olaparib (Lynparza) as a central component of maintenance therapy for patients with BRCA-mutated ovarian cancer, according to Kevin Elias, MD.^1,2

“Olaparib is still very much one of the treatments of choice for women with somatic or germline [BRCA] mutations who have just finished primary therapy. We have the longest safety and efficacy data for olaparib compared with other PARP inhibitors, and we know that for this subgroup of patients, the benefit is tremendous,” Elias said during an interview with OncLive®. Elias is a gynecologic oncologist and the Lilli and Seth Harris Endowed Chair for Ovarian Cancer Research at the Cleveland Clinic in Ohio.

In the interview, Elias discussed the need for germline and somatic testing at diagnosis, the ongoing investigation of optimal treatment duration, and safety considerations associated with the use of PARP inhibitors.

OncLive: What were the key efficacy findings from the SOLO-1 and SOLO-2 trials?

Elias: The SOLO-1 and SOLO-2 trials were looking at maintenance olaparib therapy. The SOLO studies focused on individuals with germline mutations in the BRCA1 or BRCA2 genes, but in SOLO-1, patients could have somatic mutations in BRCA1 or BRCA2. SOLO-1 was looking at newly diagnosed women who had just finished primary therapy with surgery and a platinum doublet for ovarian cancer and randomized them to either maintenance olaparib therapy, which was [given at a dose of] 300 mg twice daily, or placebo for up to 2 years.

The primary outcome was progression-free survival [PFS], and for women randomized to olaparib, the chances of progression or death were reduced by 70% [compared with placebo]. It was a very positive study.

SOLO-2 was a little bit different [because it looked] at women with recurrent ovarian cancer and only focused on germline mutation carriers. All patients in SOLO-2 had received at least 2 lines of platinum-based chemotherapy and were platinum sensitive in the most recent line. These patients were also randomized to 300 mg of olaparib twice daily or placebo.

Similarly, there was also a strong PFS benefit in that setting, although the magnitude of benefit in the recurrent setting was not quite as great as in the primary setting. In SOLO-2, the median PFS in the olaparib group was 19.1 months vs 5.5 months in the placebo group.

What did the long-term data from SOLO-1 show?

The long-term survival data from SOLO-1 showed that, at 7 years from randomization, the risk of death [was reduced by 45%] for those receiving olaparib vs those in the placebo group. Almost half [45.3%] of patients in the olaparib group were still alive and had not recurred at 7 years, whereas [79.4%] of patients in the placebo group had recurred or died [within that period].

How do these data inform treatment decision-making?

[These data] highlight the importance of understanding underlying germline predisposition in ovarian cancer at initial diagnosis. The earlier we know if someone is a BRCA1 or BRCA2 mutation carrier, either at a germline or somatic level, the sooner we’re able to get them appropriately onto olaparib therapy. We can make a strong recommendation that it alters the treatment trajectory.

What I counsel my patients is that, looking across the studies with olaparib, if they’re a good candidate based on the study criteria, we can cut their risk of relapse or death by more than half by going on [PARP inhibitor] maintenance therapy.

What questions persist regarding olaparib use in ovarian cancer treatment?

We still have questions about olaparib as far as the duration of therapy. In the initial studies, all patients were randomized to 2 years of olaparib therapy. There’s currently a study funded by the NRG that’s randomizing patients to either 2 years or 1 year of maintenance therapy. Two years of therapy was chosen rather empirically, and it could be that patients might benefit from shorter courses, which would be beneficial not only in terms of cost but also [adverse] effects [AEs].

We know these medicines have a risk of myelodysplastic syndrome, and perhaps by exposing patients to shorter durations of therapy, we might reduce one of the most concerning AEs of these drugs.

References

1. DiSilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol. 2023;41(3):609-617. doi:10.1200/JCO.22.01549
2. Poveda A, Floquet A, Ledermann JA, et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol. 2020;38(suppl 15):6002. doi:10.1200/JCO.2020.38.15_suppl.6002

• The firm order for one Global 8000 aircraft was announced during NBAA-BACE 2025
• Comlux will elevate its ultra-long-range charter capabilities with Bombardier’s flagship aircraft, delivering unmatched performance and refined passenger experience
• Set to enter into service this year, the Global 8000⁽¹⁾is the fastest business jet in the world, offering the longest range in its class and the ability to operate from short runways

Bombardier is proud to announce that Comlux, a leading business aviation company, will take delivery of the industry-defining Global 8000⁽¹⁾ aircraft in 2026. Renowned for its expertise in long-range operations with aircraft such as the Bombardier Global 6000 and Global 6500, Comlux is strategically enhancing its charter offering with Bombardier’s flagship jet. With its industry-leading ultra-long-range capabilities and top speed, the Bombardier Global 8000 aircraft is the ideal complement to Comlux Aviation’s fleet—delivering exceptional performance, comfort, and efficiency for premium global travel.

“The Bombardier Global 8000 aircraft integrates perfectly into our long-range fleet, in between our wide-body fleet and our Global 6500 fleet,” said Comlux Aviation CEO, Andrea Zanetto. He continues: “At Comlux, we offer comfort in ownership and luxury in flight! We have built our reputation on delivering premium global travel solutions and this aircraft allows us to offer ultra-long-range. Comlux continuously elevates its fleet to offer clients an unmatched charter experience across the globe with a diversified fleet. The delivery of the Global 8000 will mark the beginning of an exciting new chapter, as we continue to attract more clients to manage the operation of Global 7500 and Global 8000.”

“The Bombardier Global 8000 jet offers the perfect balance of ultra-long-range performance and refined passenger experience—an ideal fit for Comlux’s discerning clientele,” said Éric Martel, President and CEO, Bombardier. “As our valued business relationship continues to grow, the Global 8000 aircraft will deliver its exceptional performance and signature smooth ride to Comlux’s customers around the world.”

The Global 8000⁽¹⁾, the world’s fastest purpose-built business jet, represents a new era of performance, comfort and innovation. With its unmatched speed and a range of 8,000 nautical miles, the aircraft is designed to meet the needs of the most discerning travelers—delivering seamless connectivity between global cities with exceptional onboard luxury.

Comlux’s upcoming delivery marks a significant milestone in the continued adoption of the Bombardier Global 8000 jet by leading operators worldwide. The aircraft’s advanced technology and refined cabin experience make it a standout choice for those seeking the ultimate in private aviation.

About Bombardier

At Bombardier (BBD-B.TO), we design, build, modify and maintain the world’s best-performing aircraft for the world’s most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs.

For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it.

Bombardier customers operate a fleet of more than 5,100 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service facilities across six countries.

 Bombardier’s performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico. In 2024, Bombardier was honoured with the prestigious “Red Dot: Best of the Best” award for Brands and Communication Design.     

About Comlux

Comlux Group is one of the leaders in business aviation industry. For over 20 years, the company has been engineering luxury for VIP customers seeking personal and professional management of their private aviation needs, including aircraft sales and acquisitions, aircraft operations and charter management. Headquartered in Switzerland with a global presence around the world, Comlux delivers world-class, Swiss-made business aviation services.

For Information

For corporate news and information, including Bombardier’s Sustainability report, as well as the company’s initiative to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book-and-Claim system visit
bombardier.com.

Learn more about Bombardier’s industry-leading products and customer service network at bombardier.com. Follow us on X @Bombardier.

Media Contacts

General media contact webform

Bombardier, Global, Global 6000, Global 6500, Global 7500 and Global 8000 are registered or unregistered trademarks of Bombardier Inc. or its subsidiaries. 

⁽¹⁾The Global 8000 aircraft is currently under development and remains to be finalized and certified. It is expected to enter into service in 2025. See forward-looking statements disclaimer hereafter. All specifications and data are approximate and may change without notice and are subject to certain operating rules, assumptions and conditions. 

Forward-looking statements 

This press release contains certain forward-looking statements. By their nature, forward-looking statements require the Corporation to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause actual results in future periods to differ materially from those set forth in the forward-looking statements. Please refer to the “Forward-Looking Statements” disclaimer contained in Bombardier Inc.’s most recently published financial report for additional details. 

(Bloomberg) — Wall Street traders lifted stocks as the US and China signaled willingness to keep trade negotiations alive, Middle East tensions cooled while the artificial-intelligence rally powered ahead.

Following its worst rout in six months, the S&P 500 jumped about 1.5% to extend a bull market that’s already added $28 trillion to its value. The benchmark saw its best session since August. A key gauge of chipmakers surged 5%. Broadcom Inc. soared 10% as OpenAI agreed to buy its custom chips and networking equipment in a multiyear agreement.

Subscribe to the Stock Movers Podcast on Apple, Spotify and other Podcast Platforms.

With trade jitters easing and investors brushing aside fears of a tech-fueled bubble, the market rebound showed that the buy-the-dip mentality remains firmly in place. That’s just ahead of the unofficial start of the US earnings season, with a barrage of reports from big banks Tuesday.

“Investors remain eager for exposure, and if this recovery holds, it will reinforce the idea that retail investors can’t be easily shaken and another reminder that buying the dip continues to work,” said Mark Hackett at Nationwide.

Risk appetite increased after President Donald Trump’s administration signaled openness to a deal with China to quell fresh trade tensions while China’s Ministry of Commerce urged further negotiations to resolve outstanding issues.

Sentiment was also buoyed as Trump visited the Middle East to celebrate a deal halting the war in Gaza and securing the release of prisoners held by Hamas. Trump said food and aid has begun to flow into Gaza, which has been devastated by the conflict.

Treasury futures edged mildly lower, with the US bond market closed for Columbus Day. The dollar rose 0.2%.

Wall Street’s biggest banks are poised for another strong quarter, buoyed by resilient trading desks and a rebound in deal activity. Bank stocks have surged in recent weeks on optimism that a milder regulatory environment under the Trump administration would jump-start corporate dealmaking and boost advisory revenue.

A record-setting surge in US stocks has traders approaching the start of corporate earnings season with little patience for companies that don’t meet the bar. Investors will also be looking for reassurance on a range of potentially thorny issues, from the durability of AI spending to how elevated tariffs are impacting companies.

“This earnings season is important to gauge the overall health of the bull market. Investors will closely examine technology earnings as AI and data center capex is increasingly being called into question in terms of how this spending may or may not be leading to profits,” said Richard Saperstein at Treasury Partners.

Meantime, equity analyst sentiment toward corporate profits is losing momentum at a time when US stocks are trading near record highs, suggesting the rally could face speed bumps this earnings season.

A Citigroup Inc. index tracking US earnings revisions — the number of analysts upgrading versus downgrading estimates — has turned flat for the first time since August. At the same time, the S&P 500 is trading around 22 times forward earnings, above the average over the past decade of nearly 19 times.

Investors should buy cheap stocks with the highest track record of beating both revenue and earnings expectations ahead of the third-quarter reporting season, according to a team of strategists led by Evercore ISI’s Julian Emanuel.

With the S&P 500 already at high valuation multiples and investors bracing for tariff negotiations between US and China, earnings reactions will likely be varied and violent for stocks, the strategists said.

The rally in US stocks is likely to pause if momentum in corporate profits fades in the third quarter, RBC Capital Markets strategists wrote in a note.

“If the strong sentiment around earnings that was seen in the last reporting season can’t be maintained, we think it will be difficult for the major indices to avoid a period of digestion in very near term,” the team led by Lori Calvasina said.

The bull market in US stocks saw its third anniversary on Sunday, but if history is any guide it needs to broaden out soon to keep running.

Of the 13 prior bull markets since World War II, seven completed a fourth year, with an average total gain of 88%. This one has essentially done that in three years, putting the S&P 500’s trailing price-to-earnings ratio at 25 — the highest ever for a bull market in its third year, said Wall Street veteran and CFRA chief investment strategist Sam Stovall.

Even as Stovall thinks the bull market has a good chance of celebrating its fourth birthday, history says it may be a volatile one, he noted.

“More generally, we think that the bull market will remain intact, so pullbacks should offer an opportunity for investors who are underallocated to equities to consider adding long-term exposure,” said Ulrike Hoffmann-Burchardi at UBS Global Wealth Management.

Bull markets that made it to year four have tended to perform very well during that year, according to Jeff Buchbinder and Adam Turnquist at LPL Financial.

For the seven bull markets since 1950 that lasted at least four years, the S&P 500 has, on average, gained 12.8% during the fourth year, they said. Six of the seven mature bull markets had positive year fours, with stocks falling during the fourth year of the first bull market after World War II that began in June 1949.

While this bull market has enjoyed a strong three years, history suggests it probably has more room to run, the LPL strategists noted.

“First, we need economic growth. Recessions kill bull markets, and thankfully, we don’t see one on the horizon. The Fed is in the middle of a rate-cutting cycle and inflation appears to be under control despite increased tariffs,” they concluded.

Corporate Highlights:

Broadcom Inc. shares jumped after OpenAI agreed to buy the company’s custom chips and networking equipment in a multiyear deal, part of an ambitious plan by the startup to add artificial intelligence infrastructure. As part of the pact, OpenAI will design the hardware and work with Broadcom to develop it, according to a joint statement on Monday. The plan is to add 10 gigawatts’ worth of AI data center capacity, with the companies beginning to deploy racks of servers containing the gear in the second half of 2026. Amazon.com Inc. plans to hire 250,000 workers during its peak season — unchanged from the previous two years — making the online retailer a standout in an otherwise bleak holiday labor market. Apple Inc. is bringing its superthin iPhone Air to China after a pause that allowed local carriers to prepare for the eSIM-only device. Exxon Mobil Corp. Chief Executive Officer Darren Woods renewed criticism of the European Union’s energy policies while praising US President Donald Trump’s approach. JPMorgan Chase & Co. vowed to funnel $1.5 trillion into industries that bolster US economic security and resiliency over the next 10 years — an initiative that will invest billions of dollars in companies and hire bankers and other professionals. Oracle Corp. will get a chance this week to reassure investors that a rally which has added roughly $370 billion to its market value this year is on stable footing. The software maker is hosting a four-day AI World conference starting Monday in Las Vegas, where much of the focus will be on Oracle’s cloud computing business. Beyond Meat Inc. tumbled after the troubled plant-based protein producer said nearly all creditors had accepted a debt swap that will lead to a substantial dilution of shareholders. Keurig Dr Pepper Inc. jumped after the Financial Times reported that Starboard Value had built a stake in the beverage company. Walt Disney Co. will air a six-part docuseries on the behind-the-scenes action of Taylor Swift’s Eras Tour, the highest-grossing concert tour of all time. First Brands Group’s Chief Executive Officer Patrick James has resigned from the company. James will be replaced by Charles Moore as interim CEO, according to a company statement. Jefferies Financial Group Inc. defended its dealings with First Brands Group and said its exposure to the bankrupt auto-parts supplier was small, as the investment bank sought to revive investor confidence after a sharp selloff in its stock. Douglas Lebda, the founder and chief executive officer of LendingTree Inc., died Sunday following an all-terrain vehicle accident. He was 55. Airbus SE is opening additional assembly lines in the US and China for its bestselling A320neo family as the company tries to reach production of 75 jets a month amid a massive backlog. Virgin Atlantic Airways Chief Executive Officer Shai Weiss will step down after a seven-year tenure marked by returning the UK airline to an annual profit. Brookfield will acquire the remaining parts of distressed-debt specialist Oaktree Capital Management it doesn’t already own, adding further heft to its credit business that’s emerged as a key driver of growth in recent years. Tata Capital Ltd. advanced in its Mumbai trading debut after the shadow lender wrapped up its 155-billion-rupee ($1.7 billion) initial public offering, India’s biggest this year. What Bloomberg Strategists say…

“In the absence of official data, what banks can say about credit card losses, loan losses, credit quality and the pulse of the consumer will go a long way toward filling the data void.”

– Edward Harrison, Macro Strategist, Markets Live. For the full analysis, click here.

Some of the main moves in markets:

Stocks

The S&P 500 rose 1.4% as of 2:58 p.m. New York time The Nasdaq 100 rose 2% The Dow Jones Industrial Average rose 1.1% The MSCI World Index rose 1% Bloomberg Magnificent 7 Total Return Index rose 2.2% Philadelphia Stock Exchange Semiconductor Index rose 4.7% The Russell 2000 Index rose 2.6% Broadcom rose 9.5% Currencies

The Bloomberg Dollar Spot Index rose 0.2% The euro fell 0.4% to $1.1568 The British pound fell 0.2% to $1.3333 The Japanese yen fell 0.7% to 152.31 per dollar Cryptocurrencies

Bitcoin rose 0.2% to $115,203.04 Ether rose 2.2% to $4,231.59 Bonds

Germany’s 10-year yield was little changed at 2.64% Britain’s 10-year yield declined two basis points to 4.66% Commodities

West Texas Intermediate crude rose 1% to $59.47 a barrel Spot gold rose 2.1% to $4,101.02 an ounce ©2025 Bloomberg L.P.